Barthold, Douglas http://orcid.org/0000-0003-0511-5520
Brah, Aaron T.
Graham, Susan M.
Simoni, Jane M.
Hauber, Brett http://orcid.org/0000-0003-3129-7268
Funding for this research was provided by:
National Institutes of Health (R01 MH121424, AI027757)
Article History
Accepted: 10 April 2022
First Online: 21 May 2022
Declarations
:
: Financial support for this study was provided in part by a grant from the National Institutes of Health (NIH) [R01 MH121424], and by the University of Washington/Fred Hutch Center for AIDS Research, an NIH-funded program under award number AI027757, which is supported by the following NIH institutes and centers: NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA, NIGMS, NIDDK. The funding agreements ensured the authors’ independence in designing the study, interpreting the data, and writing and publishing the report.
: Brett Hauber was an employee of RTI Health Solutions at the time this research was conducted. Susan M. Graham has received support from Gilead and Cepheid. Jane M. Simoni has received support from Pfizer. Douglas Barthold and Aaron T. Brah have no conflicts of interest directly relevant to the content of this article.
: Institutional review board approval for the entire study (including key informant interviews, pilot testing, and the full survey) was granted by the University of Washington Human Subjects Division (STUDY00007390).
: Not applicable.
: Not applicable.
: The data are confidential.
: Details of code and methods not specified in the article are available upon request.
Free to read: This content has been made available to all.